Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: A 5-year-follow-up study

Tumori

Volumn 98, Issue 6, 2012, Pages 751-755

  Chen, Yan Bin ^a   Mu, Chuan Yong ^a   Huang, Jian An ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Immunohistochemistry; Non small cell lung cancer; Overall survival time; Programmed death 1 ligand 1

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1;

ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PREDICTION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; UPREGULATION;

ADULT; AGED; ANTIGENS, CD274; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84873666114     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1217.13499     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin, 62: 10-29, 2012.
2. Zhao P, Dai M, Chen W, Li N: Cancer trends in China. Jpn J Clin Oncol, 40: 281-285, 2010.
3. Sengupta N, MacFie TS, MacDonald TT, Pennington D, Silver AR: Cancer immunoediting and "spontaneous" tumor regression. Pathol Res Pract, 206: 1-8, 2010.
4. Kim R, Emi M, Tanabe K: Cancer immunoediting from immune surveillance to immune escape. Immunology, 121: 1-14, 2007.
5. Archibald DJ, Neff BA, Voss SG, Splinter PL, Driscoll CL, Link MJ: B7-H1 expression in vestibular schwannomas. Otol Neurotol, 31: 991-997, 2010.
6. Dong H, Zhu G, Tamada K, Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin 10 secretion. Nat Med, 5: 1365-1369, 1999.
7. Kashani-Sabet M: Tumor progression by immune evasion in melanoma: role of the programmed cell death-1/programmed cell death-1 ligand 1 interaction. Cancer, 116: 1623-1625, 2010.
8. Detterbeck FC, Boffa DJ, Tanoue LT: The new lung cancer staging system. Chest, 136: 260-271, 2009.
9. Krleza-Jeri K, Lemmens T: 7th revision of the Declaration of Helsinki: good news for the transparency of clinical trials. Croat Med J, 50: 105-110, 2009.
10. Beasley MB, Brambilla E, Travis WD: The 2004 World Health Organization classification of lung tumors. Semin Roentgenol, 40: 90-97, 2005.
11. Tanoue LT, Detterbeck FC: New TNM classification for non-small-cell lung cancer. Expert Rev Anticancer Ther, 9: 413-423, 2009.
12. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG: High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol, 28: 682-688, 2011.
13. Friedrichs K, Gluba S, Eidtmann H, Jonat W: Overexpression of p53 and prognosis in breast cancer. Cancer, 72: 3641-3647, 1993.
14. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med, 192: 1027-1034, 2000.
15. Finger LR, Pu J, Wasserman R, Vibhakar R, Louie E, Hardy RR: The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. Gene, 197: 177-187, 1997.
16. Sharpe AH, Freeman GJ: The B7-CD28 superfamily. Nat Rev Immunol, 2: 116-126, 2002.
17. Wang L, Ma Q, Chen X, Guo K, Li J, Zhang M: Clinical significance of b7-h1 and b7-1 expressions in pancreatic carcinoma. World J Surg, 34: 1059-1065, 2010.
18. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS: Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A, 101: 17174-17179, 2004.
19. Chen X, Liu S, Wang L, Zhang W, Ji Y, Ma X: Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. Cancer Biol Ther, 7: 622-627, 2008.
20. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N: Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res, 11: 2947-2953, 2005.
21. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N: Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem, 108: 19-24, 2006.
22. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y: Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res, 15: 971-979, 2009.
23. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H: Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res, 13: 2151-2157, 2007.
24. Geng L, Huang D, Liu J, Qian Y, Deng J, Li D: B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol, 134: 1021-1027, 2008.
25. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S: Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother, 56: 1173-1182, 2007.
26. Tunuguntla HS, Jorda M: Diagnostic and prognostic molecular markers in renal cell carcinoma. J Urol, 179: 2096-2102, 2008.
27. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS: Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer, 104: 2084-2091, 2005.
28. Routh JC, Ashley RA, Sebo TJ, Lohse CM, Husmann DA, Kramer SA: B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence. J Urol, 179: 1954-1959, 2008.
29. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A, 104: 3360-3365, 2007.
30. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G: The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important highrisk prognostic factors. Neoplasia, 8: 190-198, 2006.
31. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M: B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res, 10: 5094-5100, 2004.
32. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med, 8: 793-800, 2002.
33. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99: 12293-12297, 2002.
34. Tamura H, Ogata K, Dong H, Chen L: Immunology of B7-H1 and its roles in human diseases. Int J Hematol, 78: 321-328, 2003.
35. Blank C, Gajewski TF, Mackensen A: Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother, 54: 307-314, 2005.
36. Blank C, Mackensen A: Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother, 56: 739-745, 2007.
37. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B: Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer, 119: 317-327, 2006.
38. Tsushima F, Yao S, Shin T, Flies A, Flies S, Xu H: Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood, 110: 180-185, 2007.
39. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L: B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood, 111: 3635-3643, 2008.
40. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM: Safety and activity of anti-pd-l1 antibody in patients with advanced cancer. N Engl J Med, 366: 2455-2465, 2012.
41. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 366: 2443-2454, 2012.